Krenitsky; Paul John

Patent Applications and Registrations

Patent applications and USPTO patent grants for Krenitsky; Paul John.The latest application filed is for "modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator".

Company Profile

8.9.11

Krenitsky; Paul John - San Diego CA
Krenitsky; Paul John - Boston MA
Krenitsky; Paul John - Newark DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator App 20220306606 - Alcacio; Timothy ; et al.	2022-09-29
Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Grant 11,453,655 - Abela , et al. September 27, 2	2022-09-27
Modulators of cystic fibrosis transmembrane conductance regulator Grant 11,426,407 - Miller , et al. August 30, 2	2022-08-30
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Grant 11,186,566 - Alcacio , et al. November 30, 2	2021-11-30
Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator App 20210052584 - Miller; Mark Thomas ; et al.	2021-02-25
Modulator Of The Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator App 20210047295 - Abela; Alexander Russell ; et al.	2021-02-18
Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Grant 10,793,547 - Abela , et al. October 6, 2	2020-10-06
Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process App 20200283405 - Alcacio; Timothy ; et al.	2020-09-10
Modulators of cystic fibrosis transmembrane conductance regulator Grant 10,758,534 - Miller , et al. Sep	2020-09-01
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator Grant 10,570,115 - Alcacio , et al. Feb	2020-02-25
Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator App 20190269683 - Miller; Mark Thomas ; et al.	2019-09-05
Modulators of cystic fibrosis transmembrane conductance regulator Grant 10,258,624 - Miller , et al.	2019-04-16
Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator App 20180185364 - Miller; Mark Thomas ; et al.	2018-07-05
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator App 20180162839 - Abela; Alexander Russell ; et al.	2018-06-14
Modulator of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulator App 20180093969 - Alcacio; Timothy ; et al.	2018-04-05
Modulators of cystic fibrosis transmembrane conductance regulator Grant 9,782,408 - Miller , et al. October 10, 2	2017-10-10
Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator App 20170196862 - Miller; Mark Thomas ; et al.	2017-07-13
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator App 20160095858 - Miller; Mark Thomas ; et al.	2016-04-07
1N-alkyl-n-arylpyrimidinamines and derivatives thereof Grant 6,342,503 - Aldrich , et al. January 29, 2	2002-01-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.